

CSD/BSE&NSE/CC/2024-25

November 06, 2024

To  
The Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**Scrip Code: 543064**

**Scrip Symbol: SUVENPHAR**

Dear Sir/Madam,

**Sub: Schedule of Conference Call for Investors**

.....

With reference to above subject, please find enclosed intimation regarding schedule of conference call for investors on **Tuesday, November 12, 2024 at 06.30 p.m. IST to discuss the Un-audited Financial Results for the Q2 & H1FY25**, to be declared on November 12, 2024.

This is for your information and record.

Thanking You.

Yours faithfully,  
For **Suven Pharmaceuticals Limited**

**Kundan Kumar Jha**  
*Company Secretary, Compliance Officer and Head-Legal*

Encl: as above

## **Suven Pharmaceuticals Limited**

**Registered Office:** # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India  
Tel: 91 22 61539999

**Corporate Office:** # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India  
Tel: 91 40 2354 9414 / 3311

Email: [info@suvenpharm.com](mailto:info@suvenpharm.com) | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | CIN: L24299MH2018PLC422236



---

## Suven Pharmaceuticals Ltd to host Q2 & H1FY25 Results Conference call on Tuesday, November 12, 2024 @ 6.30 pm

---

Suven Pharmaceuticals Ltd will conduct a conference call to discuss its Q2 & H1FY25 results performance. The management team will be represented by Mr. Vivek Sharma (Executive Chairman), Dr. V Prasada Raju (Managing Director), Dr. Sudhir Kumar Singh (Chief Executive Officer) & Mr. Himanshu Agarwal (Chief Financial Officer).

The conference call will be initiated with a brief discussion after which the floor will be opened for Q&As. The financial results will be announced earlier on November 12, 2024.

In order to pre-register: Copy this URL in your browser:

[https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=1767413  
&linkSecurityString=bc11a94a4](https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=1767413&linkSecurityString=bc11a94a4)

### Details of the conference call are as follows:

---

<b>Timing</b>	6.30 pm IST on Tuesday, November 12, 2024
<hr/>	
<b>Conference dial-in</b>	
Primary number	+91 22 6280 1141/+91 22 7115 8042
Singapore Toll Free Number	800 101 2045
Hong Kong Toll Free Number	800 964 448
USA Toll Free Number	1 866 746 2133
UK Toll Free Number	0 808 101 1573

---

- ENDS -

### For further information please contact

Cyndrella Carvalho, (Head – Investor Relations)  
Suven Pharmaceuticals Limited  
Tel: +91 40 2354 9414  
Email: [cyndrella.carvalho@suvenpharm.com](mailto:cyndrella.carvalho@suvenpharm.com)

Gavin Desa / Rishab Barar  
CDR India  
Tel: +91 98206 37649 / 77770 35061  
Email: [gavin@cdr-india.com](mailto:gavin@cdr-india.com)  
[rishab@cdr-india.com](mailto:rishab@cdr-india.com)